Aristea Therapeutics (Aristea) is clinical-stage drug development company that develops novel therapies for treating serious inflammatory diseases. Today it made the announcement about its Scientific Advisory Board (SAB), which comprises of industry experts in inflammatory and dermatological disease drug development. SAB is to work closely with Aristea’s leadership for advancing its lead therapeutic, RIST4721, for the patients with palmoplantar pustulosis (PPP), a chronic inflammatory skin condition without any approved therapy in the US. SAB is also to assist the Aristea management team in planned development of added indications for RIST4721 along with expansion and succeeding development of the Aristea portfolio.
President and CEO of Aristea Therapeutics, Dr James Mackay said that they were privileged to work with Brian, Michael, Camilla and Jay for bringing patients with PPP, a novel therapeutic treatment. These leaders helped in understanding of inflammatory and dermatological diseases, along with having expertise in development and commercialization of a lot of important drugs. They looked forward to their contributions as they advanced RIST4721 through Phase 2 along with other assets they add to Aristea portfolio as they continued to grow.
Brian Kotzin , member of SAB:
Brian Kotzin is a board-certified rheumatologist and internist who has experience in fields of inflammation and immunology in academia and industry for more than 3 decades. He is M.D. and Chair of Aristea’s SAB,. Currently, he is Senior Vice President, Clinical Development at Nektar Therapeutics, Inc. Before Nektar, he was Vice President of Global Clinical Development and Head of Inflammation Therapeutic Area at Amgen. He directed global development efforts for inflammation product candidates of Amgen. At Amgen, he was also Vice President of Medical Sciences. He was also Head of Clinical Immunology in Department of Medicine and Director of Autoimmunity Center of Excellence at University of Colorado Health Sciences Center in Denver. He has authored over 200 publications in medical journals, book chapters and books, and has served on editorial boards of Arthritis and Rheumatism, The Journal of Immunology and the Journal of Clinical Investigation. He did his B.S. in mathematics from University of Southern California and his M.D. from Stanford University School of Medicine. He did fellowship in rheumatology and medicine at Beth Israel Hospital in Boston and residency in internal medicine. He was postdoctoral fellow in Division of Immunology and Rheumatology at Stanford University School of Medicine. He is board certified in rheumatology and internal medicine.